Company intelligence / Profile preview

VibioSphen

Labege, Occitanie, Francevibiosphen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

VibioSphen specializes in preclinical research and development of therapies for infectious diseases. The company offers CRO services using predictive pharmacological models for bacteria, fungi, and viruses. Its internal R&D focuses on immunomodulatory treatments complementary to antibiotics and the identification of new anti-infective compounds from natural products. As of now, all programs are at the preclinical stage with no clinical trial results reported publicly.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologicNatural productImmune modulator therapy
Industry: Biotech

Partnerships

Pierre Fabre

Beyond the preview

Go deeper on VibioSphen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VibioSphen.

Explore the full profile